Hero image with Pittsburgh background pittplusme.org/study/1367

STUDY BASICS

Have you been diagnosed with relapsed (comes back) or refractory (did not get better) multiple myeloma? If so, you may be eligible to participate in a study to help researchers test whether an investigational (experimental) drug called venetoclax combined with dexamethasone works better than the combination of pomalidomide and dexamethasone to treat multiple myeloma. Compensation provided.


IRB:
  20181482 - A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple Myeloma

Age Range
AGE:   18 and up

Location LOCATION: 
UPMC Cancer Center
Compensation COMPENSATION: 

$56.00 per completed visit

Phone Number PHONE NUMBER:
1-866-438-8230
I'M INTERESTED
SHARE STUDY
Printer Printer   Email A FriendEmail A Friend   ShareShare   TweetTweet   Linked-InLinked-In
Search Icon pittplusme.org/study/1367
OR
Phone Number PHONE NUMBER:
1-866-438-8230

MEET THE RESEARCHER


Anastasios Raptis

Anastasios Raptis, MD, PhD, is a Clinical Assistant Professor of Medicine at the University of Pittsburgh School of Medicine. A graduate of the University of Ioannina in Greece, Dr. Raptis’ research interests include hematological malignancies, leukemia, myelodysplastic syndrome, Hodgkin’s and non-Hodgkin’s lymphoma, and multiple myeloma.




PittPlusMe.org 1-866-438-8230 PittPlusMe@pitt.edu
@PittPlusMe share tweet